FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
38.23M
52.17M
32.41M
24.09M
41.27M
26.2M
22.32M
19.01M
16.2M
13.8M
Total Cash %
1.38
2.97
2.06
1.73
2.99
2.23
2.23
2.23
2.23
Receivables
445.9M
258.5M
193.03M
199.72M
147.77M
160.43M
136.68M
116.44M
99.2M
84.51M
Receivables %
16.14
14.7
12.29
14.38
10.71
13.64
13.64
13.64
13.64
Inventories
534.51M
364.68M
421.48M
363.15M
276.42M
265.98M
226.6M
193.05M
164.47M
140.12M
Inventories %
19.35
20.74
26.84
26.15
20.03
22.62
22.62
22.62
22.62
Payable
400.98M
296.77M
251.07M
287.61M
249.88M
202.7M
172.69M
147.12M
125.34M
106.78M
Payable %
14.52
16.87
15.99
20.71
18.1
17.24
17.24
17.24
17.24
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Cap Ex %
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
